Screener
Amphastar Pharmaceuticals AMPH Current Debt
Current Debt at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent.
The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:50 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001297184-26-000047
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable and accrued liabilities | $251,371 | $148,348 |
| Income taxes payable | 546 | 239 |
| Current portion of long-term debt | 2,488 | 1,641 |
| Current portion of operating lease liabilities | 8,800 | 7,928 |
| Total current liabilities | 263,205 | 158,156 |
| Long-term reserve for income tax liabilities | 5,926 | 5,926 |
| Long-term debt, net of current portion and unamortized debt issuance costs | 609,564 | 608,749 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Amphastar Pharmaceuticals's current debt?
- Amphastar Pharmaceuticals (AMPH) reported current debt of $2.49M in Q2 2026.
- How has Amphastar Pharmaceuticals's current debt changed year-over-year?
- Amphastar Pharmaceuticals's current debt increased by 168.4% year-over-year, from $927K to $2.49M.
- What is the long-term trend for Amphastar Pharmaceuticals's current debt?
- Over 5 years (2020 to 2025), Amphastar Pharmaceuticals's current debt has grown at a -33.1% compound annual growth rate (CAGR), from $12.26M to $1.64M.
- What does current debt mean?
- The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.
Ask your AI about Amphastar Pharmaceuticals's current debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude